Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective...
Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen. WALTHAM, Mass., Jan. 21,...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen
Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without some of the side...
View ArticleActelion obtains an option to in-license vamorolone from ReveraGen (Actelion...
(Source: Actelion Ltd) Vamorolone, a novel compound for the treatment of Duchenne Muscular Dystrophy, holds potential to better preserve muscle function and prolong ambulation for the patient, without...
View ArticlePositive Phase II top-line results of Lorediplon (Ergomed plc)
(Source: Ergomed plc) PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed announces positive Phase II top-line results of co-development partner Ferrer's Lorediplon for the treatment of insomnia London, UK - 6...
View ArticleEisai and Purdue Pharma Enter Worldwide Collaboration to Develop and...
WOODCLIFF LAKE, N.J. and STAMFORD, Conn., Aug. 31, 2015 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma L.P. announced today that they have entered...
View ArticleEISAI INITIATES PHASE 2 CLINICAL TRIAL TO EVALUATE LEMBOREXANT IN THE...
(Source: Purdue Pharma LP) WOODCLIFF LAKE, N.J., and STAMFORD, Conn, Oct. 31, 2016 - Eisai and Purdue Pharma L.P. announced today the initiation of a multi-center, randomized Phase 2 clinical study...
View ArticleErgomed announces positive Phase II top-line results of co-development...
(Source: Ergomed plc) London, UK - 6 Febuary 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and...
View ArticleActelion is granted marketing authorization for Uptravi (selexipag) in...
(Source: Nippon Shinyaku Co Ltd) May 17. 2016 ・Marketing authorization granted by European Commission on 12 May 2016 ・First European Union (EU) market introduction to commence in the near future...
View ArticleEISAI TO INITIATE PHASE II CLINICAL STUDY OF DUAL OREXIN RECEPTOR ANTAGONIST...
(Source: Eisai Co Ltd) Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, 'Eisai') announced today the initiation of a Phase II clinical study of its internally-discovered oral dual orexin...
View ArticleEisai Demonstrates Efficacy of Investigational Dual Orexin Receptor...
Presented at 53rd American College of Neuropsychopharmacology Annual Meeting Tokyo, Dec 10, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that...
View ArticleDesperately Seeking Shut-Eye
In the early 1970s, a colleague of Stanford University’s William Dement remarked on the resemblance of a narcolepsy patient’s symptoms to those of a recent canine patient he had read about. The...
View ArticleActelion announces excellent financial results for 2016
ALLSCHWIL/BASEL, SWITZERLAND - 14 February 2017 - Actelion Ltd (SIX: ATLN) today announced its results for the full year 2016. FINANCIAL HIGHLIGHTS Sales growing to CHF 2,412 million (+15% at CER)...
View ArticleActelion announces excellent financial results for 2016 (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 14 February 2017- Actelion Ltd (SIX: ATLN) today announced its results for the full year 2016. FINANCIAL HIGHLIGHTS Sales growing to CHF 2,412...
View ArticleActelion receives marketing approval for Opsumit (macitentan) in pulmonary...
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 March 2015 - Actelion (SIX: ATLN) announced today that Japan's Ministry of Health, Labor and Welfare granted marketing approval for Opsumit®...
View ArticleActelion creates Vaxxilon together with the Max Planck Society (Actelion Ltd)
(Source: Actelion Ltd) ALLSCHWIL, SWITZERLAND - 26 June 2015 - Actelion Ltd (SIX: ATLN) today announced the creation of a start-up, together with the Max Planck Society, in the field of synthetic...
View ArticleActelion to present at the 33rd J.P. Morgan Healthcare Conference -...
(Source: Actelion Ltd) ALLSCHWIL/BASEL, SWITZERLAND - 12 January 2015- Actelion Ltd (SIX: ATLN) announced today that Jean-Paul Clozel, Chief Executive Officer of Actelion, will present at the J. P....
View ArticleJohnson & Johnson to Acquire Actelion for $30 Billion With Spin-Out of New...
(Source: Janssen Pharmaceuticals Inc) Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion Shareholders to Receive $280...
View ArticleJOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH SPIN-OUT OF NEW...
For Immediate Release� Actelion Shareholders to Receive $280 Per Actelion Share in All-Cash Tender Offer to be Launched by Johnson & Johnson and One Share of New R&D Company for Each Actelion...
View ArticleCORRECTION: JOHNSON & JOHNSON TO ACQUIRE ACTELION FOR $30 BILLION WITH...
(Source: Actelion Ltd) In the previous press release the companies omitted the cash amount with which R&D NewCo will launch. This has now been rectified and noted as CHF 1 billion. Actelion...
View Article